In particular, the programmed death-1(PD-1)/PD-1 ligand (PD-L1) inhibitor is highly effective in solid tumors, including cervical cancer, and has been approved by the Food and Drug Administration (FDA). The gene discussed is CD274; the disease is cervical carcinoma.